

Silvia Bolognin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3065358/publications.pdf>

Version: 2024-02-01

57
papers

2,700
citations

257450

24
h-index

189892

50
g-index

69
all docs

69
docs citations

69
times ranked

3723
citing authors

#	ARTICLE	IF	CITATIONS
1	Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by β -Hydroxypropyl- β -Cyclodextrin Treatment. <i>Movement Disorders</i> , 2022, 37, 80-94.	3.9	37
2	Structural Plasticity of Dopaminergic Neurons Requires the Activation of the D3R-nAChR Heteromer and the PI3K-ERK1/2/Akt-Induced Expression of c-Fos and p70S6K Signaling Pathway. <i>Molecular Neurobiology</i> , 2022, 59, 2129-2149.	4.0	5
3	A Triple Combination of Targeting Ligands Increases the Penetration of Nanoparticles across a Blood-Brain Barrier Culture Model. <i>Pharmaceutics</i> , 2022, 14, 86.	4.5	8
4	Epitope imprinting of alpha-synuclein for sensing in Parkinson's brain organoid culture medium. <i>Biosensors and Bioelectronics</i> , 2021, 175, 112852.	10.1	26
5	Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation. <i>Neurobiology of Aging</i> , 2021, 99, 65-78.	3.1	14
6	Integrated, automated maintenance, expansion and differentiation of 2D and 3D patient-derived cellular models for high throughput drug screening. <i>Scientific Reports</i> , 2021, 11, 1439.	3.3	20
7	Monitoring the neurotransmitter release of human midbrain organoids using a redox cycling microsensor as a novel tool for personalized Parkinson's disease modelling and drug screening. <i>Analyst</i> , 2021, 146, 2358-2367.	3.5	22
8	Transition metal dichalcogenides to optimize the performance of peptide-imprinted conductive polymers as electrochemical sensors. <i>Mikrochimica Acta</i> , 2021, 188, 203.	5.0	11
9	The Parkinson's disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1. <i>Cell Reports</i> , 2021, 37, 109864.	6.4	20
10	Reduced astrocytic reactivity in human brains and midbrain organoids with PRKN mutations. <i>Npj Parkinson's Disease</i> , 2020, 6, 33.	5.3	30
11	Peptide-Imprinted Poly(hydroxymethyl 3,4-ethylenedioxythiophene) Nanotubes for Detection of β -Synuclein in Human Brain Organoids. <i>ACS Applied Nano Materials</i> , 2020, 3, 8027-8036.	5.0	26
12	Single-cell transcriptomics reveals multiple neuronal cell types in human midbrain-specific organoids. <i>Cell and Tissue Research</i> , 2020, 382, 463-476.	2.9	30
13	A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinson's disease. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	24
14	Machine learning-assisted neurotoxicity prediction in human midbrain organoids. <i>Parkinsonism and Related Disorders</i> , 2020, 75, 105-109.	2.2	41
15	Impaired serine metabolism complements LRRK2-G2019S pathogenicity in PD patients. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 48-55.	2.2	13
16	Modeling Parkinson's disease in midbrain-like organoids. <i>Npj Parkinson's Disease</i> , 2019, 5, 5.	5.3	204
17	Neural Stem Cells of Parkinson's Disease Patients Exhibit Aberrant Mitochondrial Morphology and Functionality. <i>Stem Cell Reports</i> , 2019, 12, 878-889.	4.8	68
18	Synapse alterations precede neuronal damage and storage pathology in a human cerebral organoid model of CLN3-juvenile neuronal ceroid lipofuscinosis. <i>Acta Neuropathologica Communications</i> , 2019, 7, 222.	5.2	49

#	ARTICLE	IF	CITATIONS
19	3D Cultures of Parkinson's Disease-Specific Dopaminergic Neurons for High Content Phenotyping and Drug Testing. <i>Advanced Science</i> , 2019, 6, 1800927.	11.2	92
20	Altered Expression of Circulating Cdc42 in Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1477-1483.	2.6	15
21	Millifluidic culture improves human midbrain organoid vitality and differentiation. <i>Lab on A Chip</i> , 2018, 18, 3172-3183.	6.0	108
22	Rac1 activation links tau hyperphosphorylation and A β dysmetabolism in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2018, 6, 61.	5.2	49
23	Derivation of Human Midbrain-Specific Organoids from Neuroepithelial Stem Cells. <i>Stem Cell Reports</i> , 2017, 8, 1144-1154.	4.8	321
24	Rapid and robust generation of long-term self-renewing human neural stem cells with the ability to generate mature astroglia. <i>Scientific Reports</i> , 2015, 5, 16321.	3.3	44
25	Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 557-564.	2.6	15
26	Detection of CFTR protein in human leukocytes by flow cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2014, 85, 611-620.	1.5	28
27	The Potential Role of Rho GTPases in Alzheimer's Disease Pathogenesis. <i>Molecular Neurobiology</i> , 2014, 50, 406-422.	4.0	36
28	Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. <i>Neurobiology of Aging</i> , 2014, 35, 2134-2146.	3.1	45
29	Metallothioneins and the Central Nervous System: From a Deregulation in Neurodegenerative Diseases to the Development of New Therapeutic Approaches. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 29-42.	2.6	20
30	O2-06-04: A NOVEL PHARMACOLOGIC THERAPEUTIC APPROACH TO ALZHEIMER DISEASE AND COGNITIVE AGING. , 2014, 10, P175-P175.		1
31	Shifting balance from neurodegeneration to regeneration of the brain: a novel therapeutic approach to Alzheimer's disease and related neurodegenerative conditions. <i>Neural Regeneration Research</i> , 2014, 9, 1518.	3.0	17
32	A β -Amyloid-aluminum complex alters cytoskeletal stability and increases ROS production in cortical neurons. <i>Neurochemistry International</i> , 2013, 62, 566-574.	3.8	20
33	Animal Models of the Sporadic Form of Alzheimer's Disease: Focus on the Disease and Not Just the Lesions1. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 469-474.	2.6	27
34	Increased Glutaminyl Cyclase Expression in Peripheral Blood of Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 263-271.	2.6	23
35	STRUCTURAL EFFECTS OF THE AU(III) DRUG AURANOFIN ON CELL MEMBRANES AND MOLECULAR MODELS. <i>Journal of the Chilean Chemical Society</i> , 2013, 58, 2001-2004.	1.2	1
36	Rac1 Selective Activation Improves Retina Ganglion Cell Survival and Regeneration. <i>PLoS ONE</i> , 2013, 8, e64350.	2.5	26

#	ARTICLE	IF	CITATIONS
37	Microarray analysis of gene expression profiles in human neuroblastoma cells exposed to Zn and Cu complexes. <i>Future Neurology</i> , 2012, 7, 483-497.	0.5	0
38	Effects of a Copper-Deficient Diet on the Biochemistry, Neural Morphology and Behavior of Aged Mice. <i>PLoS ONE</i> , 2012, 7, e47063.	2.5	9
39	An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide. <i>Acta Neuropathologica</i> , 2012, 123, 133-151.	7.7	72
40	Aluminum, copper, iron and zinc differentially alter amyloid- β 42 aggregation and toxicity. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 877-885.	2.8	147
41	Effects of phenylpropanolamine (PPA) on in vitro human erythrocyte membranes and molecular models. <i>Biochemical and Biophysical Research Communications</i> , 2011, 406, 320-325.	2.1	8
42	Rescue of Synaptic Failure and Alleviation of Learning and Memory Impairments in a Trisomic Mouse Model of Down Syndrome. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 1070-1079.	1.7	28
43	Beta-amyloid toxicity increases with hydrophobicity in the presence of metal ions. <i>Monatshefte für Chemie</i> , 2011, 142, 421-430.	1.8	10
44	Ontogenesis and migration of metallothionein I/II-containing glial cells in the human telencephalon during the second trimester. <i>Brain Research</i> , 2010, 1327, 16-23.	2.2	7
45	STRUCTURAL EFFECTS OF VERAPAMIL ON CELL MEMBRANES AND MOLECULAR MODELS. <i>Journal of the Chilean Chemical Society</i> , 2010, 55, .	1.2	7
46	Human erythrocytes and neuroblastoma cells are affected in vitro by Au(III) ions. <i>Biochemical and Biophysical Research Communications</i> , 2010, 397, 226-231.	2.1	9
47	Interaction between Alzheimer's Amyloid- β and Amyloid- β -Metal Complexes with Cell Membranes. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 81-90.	2.6	18
48	Chelation therapy for neurodegenerative diseases. <i>Medicinal Research Reviews</i> , 2009, 29, 547-570.	10.5	82
49	Metal Ion Physiopathology in Neurodegenerative Disorders. <i>NeuroMolecular Medicine</i> , 2009, 11, 223-238.	3.4	131
50	Structural effects of tetrachloroauric acid on cell membranes and molecular models. <i>Coordination Chemistry Reviews</i> , 2009, 253, 1599-1606.	18.8	7
51	Alzheimer's disease, metal ions and metal homeostatic therapy. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 346-355.	8.7	304
52	Human cells and cell membrane molecular models are affected in vitro by chlorpromazine. <i>Biophysical Chemistry</i> , 2008, 135, 7-13.	2.8	22
53	Mutual Stimulation of Beta-Amyloid Fibrillogenesis by Cloquinol and Divalent Metals. <i>NeuroMolecular Medicine</i> , 2008, 10, 322-332.	3.4	14
54	Accumulation of copper and other metal ions, and metallothionein I/II expression in the bovine brain as a function of aging. <i>Journal of Chemical Neuroanatomy</i> , 2008, 36, 1-5.	2.1	59

#	ARTICLE	IF	CITATIONS
55	Potential pathogenic role of β -amyloid 1-42-aluminum complex in Alzheimer's disease. International Journal of Biochemistry and Cell Biology, 2008, 40, 731-746.	2.8	79
56	Role of Metal Ions in the A β ; Oligomerization in Alzheimers Disease and in Other Neurological Disorders. Current Alzheimer Research, 2008, 5, 500-507.	1.4	106
57	Destabilization of non-pathological variants of ataxin-3 by metal ions results in aggregation/fibrillogenesis. International Journal of Biochemistry and Cell Biology, 2007, 39, 966-977.	2.8	20